Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: The role of steroid 5α-reductase and steroid aromatase

BJU International

Volumn 100, Issue 2, 2007, Pages 254-257

  Pitts Jr , W Reid ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adenocarcinoma; Late onset hypogonadism; Prostate cancer; Steroid 5 reductase; Steroid aromatase

Indexed keywords

AROMATASE; CALCIUM; ESTROGEN; FISH OIL; SELENIUM; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; VITAMIN D;

BIOCHEMISTRY; EMBRYOLOGY; ESTROGEN BLOOD LEVEL; HUMAN; HYPOGONADISM; LIPID DIET; OBESITY; PITTS UNIFIED THEORY; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SPERMATOZOON COUNT; TESTOSTERONE BLOOD LEVEL; THEORY; VALIDATION STUDY;

AGE OF ONSET; AROMATASE; AROMATASE INHIBITORS; CARCINOMA; DIETARY FATS; FEMALE; HUMANS; HYPOGONADISM; MALE; NEOPLASMS; OBESITY; PROSTATIC NEOPLASMS; SEX FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 34447250531     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06896.x     Document Type: Short Survey

References (43)

1. Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K. The loss of 5 alpha reductase Type I and II mRNA expression in metastatic prostatic cancer to bone and lymph node metastasis. Clin Cancer Res 2003 9 : 1815 9
2. Pitts WR Jr. Chemoprevention of urological cancer. J Urol 2000 163 : 1260 1
3. Pitts WR Jr. Back to the future - the role of complementary medicine in urology. J Urol 2000 164 : 461
4. Carver BS, Kattan MW, Scardino PT, Easthan JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005 95 : 501 12
5. Pitts WR Jr. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU Int 2001 88 : 985 6
6. Pitts WR Jr. Effect of the dual 5a reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2005 173 : 1433 5
7. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. NEJM 2003 349 : 215 24
8. Walsh PC. Comments re: Prostate Cancer Prevention Trial, ref. #7. J Urol 2004 171 : 506
9. Pitts WR Jr. The clinical implications of the Prostate Cancer Prevention Trial (PCPT). BJU Int 2004 93 : 1120 1
10. Pitts WR Jr. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2004 46 : 133 4
11. Pitts WR Jr. The effects of 5a-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2006 176 : 408
12. Pitts WR Jr. Dietary fat and prostate cancer, molecular epidemiology of androgen metabolic loci in prostate cancer: predisposition and progression, inflammation as target for prostate cancer chemoprevention: pathological and laboratory rationale, obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004 172 : 2483 4
13. Pitts WR Jr. Genes differentially expressed in prostate cancer. BJU Int 2004 94 : 937
14. Pitts WR Jr. Early detection of prostate cancer: serendipity strikes again. JAMA 1998 279 : 1440
15. Pitts WR Jr. Communication: outcome research after radical retropubic prostatectomy for prostate cancer. JNCI 1998 90 : 1107
16. Pitts WR Jr. Prostate cancer puzzle. J Urol 1998 160 : 1441
17. Pitts WR Jr. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004 172 : 776
18. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha reductase inhibitor. J Clin Endocrinol Metab 2004 89 : 2179
19. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 2006 176 : 1387 91
20. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd: SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995 16 : 1311
21. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of human gene: implications for prostate cancer risk. Cancer Res 1995 55 : 3973
22. Yang C, Hamajima N, Iwata H et al. A49T, V89L and TA repeat polymorphisms of steroid 5 alpha reductase type II and breast cancer risk in Japanese women. Breast Cancer Res 2002 4 : R8, Epub April 25
23. Fair WR. Back to the future - the role of complementary medicine in urology. J Urol 1999 162 : 411
24. Liang T, Lino S. Inhibition of steroid 5 alpha reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992 285 : 557 62
25. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthetase (FAS) with antitumor activity. Cancer Res 2004 64 : 2070 5
26. Ross RK, Bernstein L, Lobo RA et al. 5 alpha reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992 339 : 887 9
27. Amling CL, Riffenburgh RH, Sun L et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004 22 : 431 45
28. Freedland SJ, Terris MK, Presti JC et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004 172 : 520 4
29. Ramen JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002 167 : 624 9
30. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endoc Metab 2004 89 : 1174 80
31. Scherr DS, Pitts WR Jr, Vaughan ED. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002 167 : 535 8
32. Pitts WR Jr. The clinical rationale for immediate androgen deprivation without estrogen deprivation. Clin Prostate Cancer 2003 2 : 127
33. Scherr DS, Pitts WR Jr. Review: the non-steroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003 170 : 1703 8
34. Price D, Stein B, Sieber P et al. Toremifine for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a double-blind placebo controlled phase II B clinical trial. J Urol 2006 176 : 965 70
35. Boorjian S, Ugras S, Mongan NP et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urol 2004 64 : 383 8
36. Barocas DA, Kawamoto H, Dreizin DF et al. Five alpha reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. Urology 2005 66 : 1134 9
37. Boorjian S, Barocas D, Smith E, Pitts WR Scherr DS. Hormone regulation of transitional cell carcinoma of the bladder. J Urol 2006 175 (Suppl. 202, Abs 628
38. Wang GJ, Kawamoto H, Dong S, Pitts WR Scherr DS. Aromatase expression in bladder cancer: clinical and pathologic correlation. Urology 2007 in press
39. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006 98 : 973 8
40. American Cancer Society. Cancer facts and figures 2006. Available at http://www.cancer.org/docroot/STT/stt_0_2006.asp?sitearea=STT&level=1 Accessed February 2007
41. Piccart-Gebhart MJ. Improving outcomes in early breast cancer: aromatase inhibitors in the adjuvant setting. Am J Onc Review 2005 5 (Suppl. 9 16 22
42. Fijii T, Saito M, Iwasaki E et al. Intratumor injection of small interfering RNA-targeting human papilloma virus 18, E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol 2006 29 : 541 8
43. Pitts WR Jr. Letter re: bladder tumor markers. J Urol 2006 176 : 2308